Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

AXIM® Biotech Signs Exclusive Distribution Agreement With Israel’s Rafa Pharmaceuticals


Posted on: 19 Sep 16

RAFA to Distribute Axim’s Award-Winning Cannabinoid Chewing Gum CanChew®

NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products, today announced that it has signed an exclusive distribution agreement with Israel-based Rafa Laboratories, Ltd. for distribution of its award-winning cannabinoid chewing gum CanChew.®

Under terms of the agreement, Rafa will submit AXIM® Biotech’s CanChew® to the Israeli Ministry of Health to be registered as a nutraceutical in the Country, and will market and distribute the product throughout Israel beginning in 2017. In addition, once AXIM® Biotech’s patented pharmaceutical chewing gum MedChew Rx™, which is currently in clinical trials for registration as a drug for patients suffering from pain and/or spasticity associated with MS, is approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), Rafa will submit it to be registered as a Rx drug product in Israel, and will market and distribute the product throughout the Country.

“We are pleased to have Rafa as our partner, and our distribution agreement represents an important step to enable expanded market access to our unique, cannabinoid-based products,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotechnologies. “Rafa has a 79-year history as a trusted partner to some of the world’s leading pharmaceutical companies, and we believe the Company maintains our goal to have a lasting impact on individuals’ well-being. Distribution agreements such as this one with Rafa are steps forward for AXIM to change the healthcare landscape by introducing our proprietary cannabinoid products to pharmaceutical and retail consumer markets worldwide.”

The founders and officers of AXIM® Biotech are the inventors of CanChew®, the world’s first patented controlled-release cannabinoid chewing gum containing 50 mg of hemp oil and 10 mg of cannabidiol (CBD). AXIM® Biotech holds the exclusive rights to market and distribute CanChew® Gum globally. CanChew® is a hemp CBD chewing gum with a unique oral mucosal absorbance delivery system. Features listed on the CanChew® website include:

  • Non-habit forming
  • No prescription needed
  • Available in all 50 states
  • Great-tasting mint gum has no artificial sweeteners or preservatives
  • Non-GMO, gluten free, vegan and kosher

In addition, AXIM® Biotech created a pharmaceutical breakthrough invention with the world’s first patented cannabinoid controlled-release CBD/THC (cannabidiol/tetrahydrocannabinol) chewing gum: MedChew Rx™. In clinical trials for pain and spasticity associated with MS, as featured by Reuters global news agency, MedChew Rx™ will change the way that medicine is delivered to patients worldwide. Directly compared to a sublingually delivered cannabis-based product currently on the market for MS, the Reuters article conveys the potential for MedChew Rx™ at an estimated $4.8 billion USD. MedChew Rx™ is on track to be fully registered by the EMA and FDA.

Another AXIM® Biotech patent-pending cannabis innovation in clinical trials is AX-1602. The first of its kind, AX-1602 contains CBG (cannabigerol) and other cannabinoids as a treatment for psoriasis and atopic dermatitis.  AXIM® Biotech’s core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease.

About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell, and distribute hemp-based products.

 

GlobeNewswire
globenewswire.com

Last updated on: 20/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.